Gallo Maria F, Grimes David A, Schulz Kenneth F, Helmerhorst Frans M
Family Health International, Research Triangle Park, North Carolina, USA.
Obstet Gynecol. 2004 Feb;103(2):359-73. doi: 10.1097/01.AOG.0000107298.29343.6a.
Many women and clinicians believe that combination estrogen-progestin contraceptive use can lead to weight gain. This concern can deter women from starting hormonal contraception or lead to premature quitting. This review evaluated the association between combination contraceptive use and change in body weight.
The computerized databases CENTRAL, MEDLINE, EMBASE, Popline, and LILACS (from their inception to 2002) were used to conduct this review. Known investigators and manufacturers were contacted for information about other trials not discovered in the database search.
All English-language, randomized controlled trials measuring weight change that were at least 3 treatment cycles in duration and that compared a combination contraceptive to a placebo or to a combination contraceptive that differed in drug, dosage, regimen, or study length were eligible for inclusion. Of the 570 reports of randomized controlled trials of eligible interventions that were identified, 42 trials were included in the systematic review.
TABULATION, INTEGRATION, AND RESULTS: Two reviewers independently abstracted data from the eligible trials using a standard form. Depending on the data available, the weighted mean difference using a fixed effect model with 95% confidence intervals was calculated for the mean change in weight between baseline and posttreatment measurements or the Peto odds ratio with 95% confidence intervals was calculated by using the proportion of women who gained or lost more than a specified amount of weight. The 3 placebo-controlled, randomized trials did not find evidence supporting a causal association between combination oral contraceptives or a combination skin patch and weight gain. Most comparisons from the 40 trials that compared 2 or more combination contraceptives showed no substantial difference in weight. In addition, discontinuation of combination contraceptives because of weight gain did not differ between groups when this factor was studied.
Available evidence is insufficient to determine the effect of combination contraceptives on weight, but no large effect is evident.
许多女性和临床医生认为,使用复方雌激素 - 孕激素避孕药会导致体重增加。这种担忧可能会使女性不愿开始使用激素避孕法或导致过早停药。本综述评估了复方避孕药的使用与体重变化之间的关联。
使用计算机化数据库CENTRAL、MEDLINE、EMBASE、Popline和LILACS(从其创建至2002年)进行本综述。联系了知名研究人员和制造商,以获取数据库搜索中未发现的其他试验的信息。
所有测量体重变化、持续时间至少为3个治疗周期、将复方避孕药与安慰剂或在药物、剂量、用药方案或研究时长方面不同的复方避孕药进行比较的英文随机对照试验均符合纳入标准。在确定的570篇符合条件干预措施的随机对照试验报告中,有42项试验被纳入系统评价。
制表、整合与结果:两名审阅者使用标准表格独立从符合条件的试验中提取数据。根据可得数据,使用固定效应模型计算基线与治疗后测量之间体重平均变化的加权平均差及其95%置信区间,或使用体重增加或减少超过特定量的女性比例计算Peto比值比及其95%置信区间。3项安慰剂对照随机试验未发现证据支持复方口服避孕药或复方皮肤贴片与体重增加之间存在因果关联。在40项比较2种或更多种复方避孕药的试验中,大多数比较显示体重无实质性差异。此外,在研究该因素时,因体重增加而停用复方避孕药的情况在各组之间没有差异。
现有证据不足以确定复方避孕药对体重的影响,但未发现明显的重大影响。